India’s IASST and IIT Guwahati Develop Breakthrough Organoselenium Compound Targeting Aggressive Breast Cancer

Indian scientists have created a new compound that shows promise in treating the aggressive form of breast cancer known as triple-negative breast cancer (TNBC). Developed by researchers at the Institute of Advanced Study in Science and Technology (IASST) in Guwahati, Assam, together with the Indian Institute of Technology (IIT) Guwahati, the compound targets critical survival pathways in cancer cells, including Akt/mTOR and ERK. By generating reactive oxygen species (ROS) and reducing inflammation, this novel approach triggers cancer cell death and opens a potential new path for TNBC therapy.

Targeting Tumor Growth and Spread: Early Success for Diselenide 7 in Animal Studies

To advance this approach, the research team built on earlier work in organoselenium chemistry. Under the leadership of Dr. Asis Bala at IASST, an institute operating under the Department of Science and Technology, Government of India, and Dr. Krishna P. Bhabak from the Department of Chemistry at IIT Guwahati, the scientists synthesized a compound known as 4-nitro-substituted benzylic diselenide (diselenide 7). The synthesis was achieved through nucleophilic substitution of benzylic halides with sodium–selenium derivatives, marking a coordinated effort to create a targeted therapeutic candidate.

In preclinical studies, the compound was tested in Swiss albino mice bearing breast adenocarcinoma. Results showed a significant reduction in tumor volume, inhibition of angiogenesis and metastasis, and prolonged survival compared with untreated controls. According to the researchers, these findings—published in the Journal of Medicinal Chemistry—highlight strong anticancer activity in both laboratory experiments and animal models, emphasizing its potential as a future therapeutic option for TNBC.

These results suggest the compound can disrupt several key processes that help cancer survive—such as tumor growth, blood vessel development, and the spread of cancer to other parts of the body. Most importantly, it extended overall survival, and as a result of its efficacy in both laboratory and animal studies, scientists see it as a strong candidate within the organoselenium family of molecules and an encouraging starting point for deeper research and potential drug development.

Why Triple-Negative Breast Cancer Remains a Challenge, With Survival as Low as 12% in Advanced Stages

To understand the significance of this discovery, it helps to know what makes TNBC so hard to treat. TNBC is a less common but highly aggressive form of breast cancer. It grows and spreads more quickly than most other types and is often diagnosed at a later stage, contributing to a poorer outlook. The name “triple‑negative” reflects the absence of estrogen and progesterone receptors and HER2 overexpression—markers that many treatments target—leaving chemotherapy as the main—and often limited—therapeutic option. TNBC accounts for about 10–15% of all breast cancer cases and disproportionately affects younger women, particularly those under 40, as well as individuals with BRCA1 mutations.

Real-World Context: Age Groups & Survival Rates

• Age trends: TNBC is more frequently diagnosed in younger women and those with BRCA1 mutations. Studies also show that younger patients often have more aggressive tumors, while older patients may face poorer outcomes partly due to less aggressive treatment.

• 5-year survival rates (SEER data):
  • Localized TNBC (confined to the breast only): ~91% survival
    Regional spread (to nearby lymph nodes or chest wall): ~65–66% survival
  • Distant/metastatic (to organs such as lungs, liver, bones, brain): ~12% survival
  • All stages combined (average across all patients): ~77% overall survival

• Longer-term outlook: Across 10 years, overall TNBC survival rates range between approximately 66% and 72%, depending on how advanced the cancer was at diagnosis. Localized cancer shows much higher long-term survival, while metastatic TNBC remains grim—sometimes with 10-year survival rates near zero.

How Diselenide 7 Works at the Cellular Level: Blocking Signals, Fueling Stress, and Stopping Spread

The newly synthesized compound, identified as 4-nitro-substituted benzylic diselenide (diselenide 7), attacks cancer through several mechanisms simultaneously.

• Blocking growth signals: It inhibits Akt/mTOR and ERK pathways, which are critical for cancer cell survival.
• Generating oxidative stress: It promotes reactive oxygen species that damage DNA and induce cancer cell death.
• Reducing inflammation: It suppresses pro-inflammatory signaling that normally helps tumors thrive.
• Halting spread and blood supply: In mice, it reduced angiogenesis and metastasis, slowing disease progression.

By targeting multiple survival strategies, the compound makes it harder for tumors to resist treatment.

A New Chapter in Cancer Research: Multi-Targeted Approaches

The findings highlight a growing shift toward multi-targeted anticancer strategies. Unlike single-pathway drugs, compounds such as diselenide 7 disrupt cancer survival on multiple levels—blocking growth signals, inducing stress, reducing inflammation, and halting spread. Experts note that this approach may help overcome one of the greatest challenges in oncology: treatment resistance.

India’s Ministry of Science and Technology has emphasized that the work reflects a broader global effort to develop more effective options for aggressive cancers. Researchers agree, but caution that the compound is still in its early stages. Key questions on safety, dosage, and long-term effects remain unanswered, and clinical trials will be the crucial next step before any patient applications can be considered.

For now, the organoselenium compound offers more than a promising laboratory result. It represents a potential new avenue in TNBC therapy, a field where survival rates remain stubbornly low and treatment choices limited. While much work lies ahead, the ability to shrink tumors, slow metastasis, and extend survival in preclinical models has placed this discovery on the radar of the international cancer research community.

Author

Bernice Lottering